Management of Enoxaparin for DVT Prophylaxis Based on Platelet Count

Platelet Count Thresholds for Anticoagulation

• The National Comprehensive Cancer Network recommends that enoxaparin for DVT prophylaxis should be held when platelet counts fall below 50,000/mcL due to increased bleeding risk 1
• Thrombocytopenia with platelets <50,000/mcL is considered a relative contraindication to anticoagulation, including prophylactic enoxaparin, based on the significantly increased risk of bleeding complications when platelets fall below this level 1, 2

Monitoring Recommendations

• The National Comprehensive Cancer Network recommends that following initiation of enoxaparin, hemoglobin, hematocrit, and platelet count should be checked every 2-3 days for the first 14 days 3
• After the initial 14 days, monitoring should continue every 2 weeks or as clinically indicated, with more frequent monitoring for patients at higher risk of heparin-induced thrombocytopenia (HIT) 3, 4

Special Considerations

• The American Society of Clinical Oncology notes that cancer patients are at particularly high risk for both VTE and bleeding complications, with the risk of thrombocytopenia potentially higher due to chemotherapy, bone marrow involvement, or other factors 2
• The Mayo Clinic recommends that for patients with a risk of HIT of ≥1%, platelet count monitoring every 2-3 days from day 4 to day 14 is recommended 4

Alternative Anticoagulants When Platelets Are Low

• The National Comprehensive Cancer Network suggests that fondaparinux may be considered as an alternative in patients with HIT, as it has an insignificantly low risk of causing HIT 4
• Direct oral anticoagulants (DOACs) like rivaroxaban or apixaban may be options for patients who cannot receive LMWH, though these are typically used for treatment rather than prophylaxis 3

Resuming Enoxaparin

• Enoxaparin prophylaxis can be resumed when platelet counts recover to >50,000/mcL, considering the patient's overall bleeding risk and the indication for prophylaxis 1, 2

Common Pitfalls to Avoid

• The National Comprehensive Cancer Network warns against failing to monitor platelet counts regularly in patients receiving enoxaparin, and overlooking the need for dose adjustments in patients with renal impairment, which can lead to accumulation and increased bleeding risk 3, 5, 6
• Continuing prophylactic anticoagulation in patients with active major bleeding (>2 units transfused in 24 hours) is an absolute contraindication 1